Steven A. Krilis focuses on Beta 2-Glycoprotein I, Molecular biology, Immunology, Antiphospholipid syndrome and Internal medicine. His Beta 2-Glycoprotein I study contributes to a more complete understanding of Antibody. His research in Antibody intersects with topics in Radioimmunoassay and Antigen.
The concepts of his Immunology study are interwoven with issues in Matrix metalloproteinase and Disease. The Antiphospholipid syndrome study combines topics in areas such as Autoantibody, Vascular disease and Pathogenesis. The concepts of his Anti-cardiolipin antibodies study are interwoven with issues in Antiphospholipid antibody positivity, Medical physics and Catastrophic antiphospholipid syndrome.
His scientific interests lie mostly in Immunology, Antibody, Antiphospholipid syndrome, Beta 2-Glycoprotein I and Molecular biology. His Antibody study integrates concerns from other disciplines, such as Platelet, Phospholipid, Antigen and Virology. His Antigen research is multidisciplinary, incorporating perspectives in Allergen and House dust mite.
His Antiphospholipid syndrome study combines topics in areas such as Lupus anticoagulant, Clinical trial and Intensive care medicine. His study on Beta 2-Glycoprotein I also encompasses disciplines like
His primary areas of investigation include Immunology, Antiphospholipid syndrome, Beta 2-Glycoprotein I, Internal medicine and Antibody. Steven A. Krilis frequently studies issues relating to Pharmacology and Immunology. His Antiphospholipid syndrome research is multidisciplinary, relying on both Core laboratory, Autoimmune disease, Clinical trial and Lupus anticoagulant.
Steven A. Krilis has researched Beta 2-Glycoprotein I in several fields, including Oxidative stress, Biochemistry, Pathogenesis, Inflammation and Immune system. The various areas that Steven A. Krilis examines in his Internal medicine study include Endocrinology and Cardiology. His biological study spans a wide range of topics, including Troponin, Platelet, Apoptosis and Ischemia.
Steven A. Krilis mainly investigates Immunology, Antiphospholipid syndrome, Beta 2-Glycoprotein I, Autoantibody and Colitis. His Immunology study combines topics from a wide range of disciplines, such as Posttranslational modification, Heparan sulphate and Age related. His Antiphospholipid syndrome research incorporates themes from Lupus anticoagulant and Rheumatology.
His Beta 2-Glycoprotein I study improves the overall literature in Antibody. In his study, Abortion, MEDLINE, Immunity, Obstetrical complications and Disease mechanisms is strongly linked to Pathogenesis, which falls under the umbrella field of Autoantibody. His work deals with themes such as Proinflammatory cytokine and Molecular biology, which intersect with Colitis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
S. Miyakis;M. D. Lockshin;T. Atsumi;D. W. Branch.
Journal of Thrombosis and Haemostasis (2006)
Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).
H P McNeil;R J Simpson;C N Chesterman;S A Krilis.
Proceedings of the National Academy of Sciences of the United States of America (1990)
Immunology and clinical importance of antiphospholipid antibodies.
H P McNeil;C N Chesterman;S A Krilis.
Advances in Immunology (1991)
The Pathogenesis of the Antiphospholipid Syndrome
Bill Giannakopoulos;Steven A Krilis.
The New England Journal of Medicine (2013)
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies
G. Ruiz-Irastorza;M. J. Cuadrado;I. Ruiz-Arruza;Robin L Brey.
A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection.
J E Hunt;H P McNeil;G J Morgan;R M Crameri.
Current concepts on the pathogenesis of the antiphospholipid syndrome.
Bill Giannakopoulos;Freda Passam;Soheila Rahgozar;Steven A. Krilis.
Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population
W. Shi;S. A. Krilis;B. H. Chong;S. Gordon.
Australian and New Zealand Journal of Medicine (1990)
Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity.
J E Hunt;R J Simpson;S A Krilis.
Proceedings of the National Academy of Sciences of the United States of America (1993)
Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics.
H. Patrick McNeil;Colin N. Chesterman;Steven A. Krilis.
British Journal of Haematology (1989)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: